# Mechanism of Action Study for Psoriasis

> **NCT00932113** · PHASE4 · COMPLETED · sponsor: **Tufts Medical Center** · enrollment: 33 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Adalimumab (Humira)

## Key facts

- **NCT ID:** NCT00932113
- **Lead sponsor:** Tufts Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-12
- **Final completion:** 2017-05-01
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2017-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00932113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00932113, "Mechanism of Action Study for Psoriasis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00932113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*